PE20080840A1 - Metodos para administrar agentes hipoglucemiantes de larga duracion - Google Patents
Metodos para administrar agentes hipoglucemiantes de larga duracionInfo
- Publication number
- PE20080840A1 PE20080840A1 PE2007001215A PE2007001215A PE20080840A1 PE 20080840 A1 PE20080840 A1 PE 20080840A1 PE 2007001215 A PE2007001215 A PE 2007001215A PE 2007001215 A PE2007001215 A PE 2007001215A PE 20080840 A1 PE20080840 A1 PE 20080840A1
- Authority
- PE
- Peru
- Prior art keywords
- hypoglycemiant
- lived
- agents
- methods
- administering long
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN POLIPEPTIDO QUE TIENE POR LO MENOS UN AGONISTA GLP-1, EL CUAL PROPORCIONA UNA CONCENTRACION MAXIMA DE DICHO POLIPEPTIDO DE 0,6 Nm Y UN AREA BAJO LA CURVA DE 3,5 Nm x DIA APROXIMADAMENTE, DURANTE 1 SEMANA. EL AGONISTA DE GLP-1 ES LA HORMONA INCRETINA, COMO FRAGMENTO, CONJUGADO, VARIANTE O MIMETICO DE LA MISMA, LOS CUALES PUEDEN ESTAR FUSIONADOS O NO CON ALBUMINA. DICHO COMPUESTO ES UTIL COMO HIPOGLUCEMIANTE
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82547206P | 2006-09-13 | 2006-09-13 | |
US86839106P | 2006-12-04 | 2006-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20080840A1 true PE20080840A1 (es) | 2008-08-27 |
Family
ID=39184534
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007001215A PE20080840A1 (es) | 2006-09-13 | 2007-09-11 | Metodos para administrar agentes hipoglucemiantes de larga duracion |
PE2012001061A PE20121528A1 (es) | 2006-09-13 | 2007-09-11 | Metodos para administrar agentes hipoglucemiantes de larga duracion |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012001061A PE20121528A1 (es) | 2006-09-13 | 2007-09-11 | Metodos para administrar agentes hipoglucemiantes de larga duracion |
Country Status (25)
Country | Link |
---|---|
US (3) | US8338369B2 (es) |
EP (1) | EP2073834B1 (es) |
JP (2) | JP5524620B2 (es) |
KR (1) | KR101472601B1 (es) |
CN (1) | CN103705911A (es) |
AR (1) | AR062775A1 (es) |
AU (1) | AU2007296499C1 (es) |
BR (1) | BRPI0716765A8 (es) |
CA (1) | CA2662622C (es) |
CL (1) | CL2007002634A1 (es) |
CR (1) | CR10684A (es) |
EA (1) | EA017159B1 (es) |
ES (1) | ES2442869T3 (es) |
IL (1) | IL197448A (es) |
JO (1) | JO2945B1 (es) |
MA (1) | MA30768B1 (es) |
MX (1) | MX2009002863A (es) |
MY (1) | MY149911A (es) |
NO (1) | NO20091266L (es) |
NZ (1) | NZ575419A (es) |
PE (2) | PE20080840A1 (es) |
SG (2) | SG174770A1 (es) |
TW (1) | TWI430806B (es) |
WO (1) | WO2008033888A2 (es) |
ZA (1) | ZA200901548B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE029798T2 (en) | 2005-11-04 | 2017-03-28 | Glaxosmithkline Llc | Methods of administering hypoglycemic agents |
US8748377B2 (en) * | 2008-12-10 | 2014-06-10 | Glaxosmithkline Llc | Pharmaceutical compositions |
EP2566502A4 (en) * | 2010-05-04 | 2013-10-09 | Glaxosmithkline Llc | METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION |
JP5902194B2 (ja) | 2010-12-16 | 2016-04-13 | ノヴォ ノルディスク アー/エス | Glp−1アゴニストとn−(8−(2−ヒドロキシベンゾイル)アミノ)カプリル酸の塩とを含む固形組成物 |
AU2012241894B2 (en) | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
HUE042757T2 (hu) | 2012-03-22 | 2019-07-29 | Novo Nordisk As | Szállító szert tartalmazó készítmények és elõállításuk |
HRP20231060T1 (hr) | 2012-03-22 | 2023-12-22 | Novo Nordisk A/S | Pripravci peptida glp-1 i njihova priprava |
US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
KR102272671B1 (ko) | 2013-05-02 | 2021-07-06 | 노보 노르디스크 에이/에스 | Glp-1 화합물의 경구 투여 |
DK3004155T3 (da) | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | Peptidforbindelse |
CA3024962A1 (en) | 2016-05-24 | 2017-11-30 | Takeda Pharmaceutical Company Limited | Peptide compound |
EP4299118A3 (en) | 2018-02-02 | 2024-04-10 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
TWI837615B (zh) * | 2021-03-23 | 2024-04-01 | 美商美國禮來大藥廠 | 含腸促胰島素(incretin)類似物之組合物及其用途 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
PT966297E (pt) | 1996-08-08 | 2009-03-18 | Amylin Pharmaceuticals Inc | Regulação da motilidade gastrintestinal |
US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
CZ2001690A3 (cs) * | 1998-08-28 | 2002-04-17 | Eli Lilly And Company | Způsob podávání inzulinotropních peptidů |
PT1180121E (pt) | 1999-05-17 | 2004-03-31 | Conjuchem Inc | Peptidos insulinotropicos de longa duracao |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
EP1355942B1 (en) | 2000-12-07 | 2008-08-27 | Eli Lilly And Company | Glp-1 fusion proteins |
AU2002239384B2 (en) | 2000-12-13 | 2007-01-11 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
EP1542712A2 (en) * | 2001-06-01 | 2005-06-22 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
CA2458371A1 (en) * | 2001-08-23 | 2003-03-06 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
JP2005514337A (ja) | 2001-10-18 | 2005-05-19 | ブリストル−マイヤーズ スクイブ カンパニー | ヒトグルカゴン様ペプチド−1模倣体、並びに糖尿病および関連疾患の処置におけるその使用 |
WO2003059934A2 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2005077042A2 (en) | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1997829A1 (en) | 2001-12-21 | 2008-12-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2468700A1 (en) * | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
EP1594530A4 (en) | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | HYBRID PROTEINS OF ALBUMIN |
PL1689757T3 (pl) * | 2003-11-12 | 2015-05-29 | Sino Med Int Alliance Inc | Heterocykliczne związki kwasu boronowego |
CN100577412C (zh) * | 2004-01-13 | 2010-01-06 | 旭硝子株式会社 | 多层层合体 |
JP2008501765A (ja) | 2004-06-11 | 2008-01-24 | ノボ ノルディスク アクティーゼルスカブ | Glp−1アゴニストを用いた薬剤誘発性肥満の中和 |
HUE029798T2 (en) * | 2005-11-04 | 2017-03-28 | Glaxosmithkline Llc | Methods of administering hypoglycemic agents |
EP2021014A1 (en) | 2006-05-26 | 2009-02-11 | Brystol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
-
2007
- 2007-09-11 TW TW096133808A patent/TWI430806B/zh not_active IP Right Cessation
- 2007-09-11 PE PE2007001215A patent/PE20080840A1/es not_active Application Discontinuation
- 2007-09-11 JO JO2007382A patent/JO2945B1/en active
- 2007-09-11 CL CL200702634A patent/CL2007002634A1/es unknown
- 2007-09-11 PE PE2012001061A patent/PE20121528A1/es not_active Application Discontinuation
- 2007-09-12 WO PCT/US2007/078226 patent/WO2008033888A2/en active Application Filing
- 2007-09-12 MY MYPI20090993A patent/MY149911A/en unknown
- 2007-09-12 BR BRPI0716765A patent/BRPI0716765A8/pt not_active Application Discontinuation
- 2007-09-12 AR ARP070104049A patent/AR062775A1/es not_active Application Discontinuation
- 2007-09-12 EA EA200970274A patent/EA017159B1/ru not_active IP Right Cessation
- 2007-09-12 MX MX2009002863A patent/MX2009002863A/es active IP Right Grant
- 2007-09-12 SG SG2011063856A patent/SG174770A1/en unknown
- 2007-09-12 US US12/441,152 patent/US8338369B2/en not_active Expired - Fee Related
- 2007-09-12 JP JP2009528440A patent/JP5524620B2/ja active Active
- 2007-09-12 AU AU2007296499A patent/AU2007296499C1/en not_active Ceased
- 2007-09-12 EP EP07842306.8A patent/EP2073834B1/en active Active
- 2007-09-12 SG SG10201501749WA patent/SG10201501749WA/en unknown
- 2007-09-12 ES ES07842306.8T patent/ES2442869T3/es active Active
- 2007-09-12 KR KR1020097007414A patent/KR101472601B1/ko active Protection Beyond IP Right Term
- 2007-09-12 NZ NZ575419A patent/NZ575419A/en not_active IP Right Cessation
- 2007-09-12 CA CA2662622A patent/CA2662622C/en not_active Expired - Fee Related
- 2007-09-12 CN CN201410014248.3A patent/CN103705911A/zh active Pending
-
2009
- 2009-03-04 ZA ZA2009/01548A patent/ZA200901548B/en unknown
- 2009-03-05 IL IL197448A patent/IL197448A/en active IP Right Grant
- 2009-03-23 CR CR10684A patent/CR10684A/es not_active Application Discontinuation
- 2009-03-26 NO NO20091266A patent/NO20091266L/no not_active Application Discontinuation
- 2009-03-30 MA MA31741A patent/MA30768B1/fr unknown
-
2012
- 2012-06-12 US US13/494,253 patent/US20130005652A1/en not_active Abandoned
-
2013
- 2013-07-19 US US13/946,296 patent/US20140066371A1/en not_active Abandoned
-
2014
- 2014-04-10 JP JP2014081275A patent/JP5753924B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20080840A1 (es) | Metodos para administrar agentes hipoglucemiantes de larga duracion | |
NI201200013A (es) | Composición de insulina de acción prolongada | |
ES2528346T3 (es) | Derivado de péptido insulinotrópico en el que se ha modificado su aminoácido N-terminal | |
MA32703B1 (fr) | Combinaison d'une insuline et d'un agoniste de glp 1 | |
PE20120514A1 (es) | Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica | |
CO7200249A2 (es) | Variantes de oxintomodulina de acción prolongada y métodos de producción de las mismas | |
AR065370A1 (es) | Moduladores de htra1 - pdz y htra3 pdz | |
PE20170954A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
AR052082A1 (es) | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante el incremento de la concentracion sanguinea de gelp -1 | |
CL2011003085A1 (es) | Compuestos derivados de 1-(piperidin-4-il)-pirazol, moduladores de la actividad del receptor acoplado a proteina g, gpr 119; composicion farmaceutica; uso de los compuestos en el tratamiento de la diabetes o de una morbilidad asociada con dicha diabetes. | |
ECSP19062769A (es) | Formulación de anticuerpo monoclonal anti-vrs | |
GT200500246A (es) | Combinacion de compuestos organicos | |
PE20191143A1 (es) | Nuevos compuestos como agonistas peptidicos trigonales de los receptores de glp1/glucagon/gip | |
PE20211300A1 (es) | Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer | |
CL2010001146A1 (es) | Proteina recombinante de circovirus porcino tipo 2 (pcv2); uso de la proteina recombinante para prevenir una infección por pcv2; un envase que comprende la composición inmunogénica (div exp 3475-2005). | |
ES2622444T3 (es) | Actividad trombopoyética de polipéptidos tirosil-ARNt sintetasa | |
PE20141546A1 (es) | Anticuerpos anti-cd134(ox40) y sus usos de los mismos | |
GT200600046A (es) | Terapia de combinacion | |
CO5720212A1 (es) | Composicion de anticuerpo her2 | |
PE20150900A1 (es) | Derivados de exendida-4 como agonistas duales de glp1/glucagon | |
CO6341637A2 (es) | \\\\\\\"composiciones y metodos novedosos\\\\\\\" | |
AR077016A1 (es) | Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales | |
CO6612278A2 (es) | Composición acuosa antitranspirante/desodorante | |
CL2011002761A1 (es) | Compuestos derivados de heterociclos sustituidos, inhibidores del canal romk; composición farmacéutica; y su uso para provocar diuresis, natriuresis o ambas, hipertension, insuficiencia cardiaca, insuficiencia renal aguda y crónica y síndrome nefrótico, entre otras enfermedades. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |